key: cord-0893356-010lano6
authors: Yang, Kanghui; Wang, Qiang; Su, Li; Fang, Hao; Wang, Xuejian; Gong, Jianzhi; Wang, Binghe; Xu, Wenfang
title: Design and synthesis of novel chloramphenicol amine derivatives as potent aminopeptidase N (APN/CD13) inhibitors
date: 2009-06-01
journal: Bioorganic & Medicinal Chemistry
DOI: 10.1016/j.bmc.2009.04.038
sha: 1490e55551708a2af75905b694c5fc1911c9b409
doc_id: 893356
cord_uid: 010lano6

Abstract Herein we report a series of novel chloramphenicol amine derivatives as aminopeptidase N (APN)/CD13 inhibitors. All compounds were synthesized starting from commercially available (1S,2S)-2-amino-1-(4-nitrophenyl) propane-1,3-diol. The preliminary biological screening showed that some compounds exhibited potent inhibitory activity against APN. It should be noted that one compound, 13b (IC50 =7.1μM), possess similar APN inhibitory activity compared with Bestatin (IC50 =3.0μM).

Aminopeptidase N (APN/CD13) is a Zn 2+ -dependent metalloectopeptidase existing in a wide variety of human tissues and cell lines (endothelial, epithelial, fibroblast, leukocyte, etc.). 1 APN expression is dysregulated in inflammatory diseases and in cancers (solid and hematologic tumors). APN is also a receptor for coronaviruses, the pathogenesis of upper respiratory infection. In recent years, the identification of activities of anti-APN/CD13 monoclonal antibody and natural/synthetic APN inhibitors suggests that APN plays a crucial role in modulating bioactive peptide responses (pain management, vasopressin release) and in influencing immune functions and major biological events (cell proliferation, secretion, invasion, angiogenesis). 2 Therefore, the development of APN inhibitors may be of clinically significance for the discovery of anti-cancer and anti-inflammatory agents.

For most APN inhibitors reported in literatures, so far there are four possible binding sites, including a zinc binding group (ZBG), two hydrophobic groups interacting with the S 1 and S 0 1 subsites in APN, and one appropriate group interacting with the S 0 2 subsite surrounded by several Arg residues. [3] [4] [5] It should be emphasized that among these four sites, at least three ones are necessary for a potent inhibitor. For example, AHPA ((2S,3R)-3-amino-2-hydro-xyl-4-phenylbutanoic acid) is a common scaffold in many natural APN inhibitors. The co-crystal complex of APN and Bestatin (AHPA-Leu) from Escherichia coli indicated that the hydroxyl and carbonyl belong to zinc binding group (ZBG). The phenyl ring in AHPA fragment can insert into S1 pocket and amino group in AHPA can interact with Glu 350 (Fig. 1) .

Our group has previously reported several kinds of new APN inhibitors, such as L-lysine derivates 6 , 3-galloylamido-N 0 -substituted 2,6-piperidinedione-N-acetamide peptidomimetics 7 , 1,3,4-thiadiazole derivates 8 , and AHPA (b-amino-a-hydroxyl-phenylbutanoic acid) derivates. 9 In our recent screening, compound (2R,3S)-2-amino-3-hydroxy-3-(4-nitrophenyl)propanoic acid ( Considering the structural similarity between compound 1 and AHPA, this molecule could act as a new lead compound for further chemical modification and optimization. Therefore, different amino acids and other functional groups can be coupled with compound 1 to generate diverse dipeptide and tripetide derivatives. In this article, we would like to describe the synthesis, enzymatic evaluation and possible binding mode of the chloramphenicol amine derivates.

The synthetic route of target compounds is shown in Schemes 1 and 2. Chloramphenicol amine (1S,2R)-2-amino-1-(4-nitrophenyl)propane-1,3-diol, 2) was firstly protected by (Boc) 2 O, then was selectively oxidized at the terminal hydroxyl group to give the N-Boc-protected acid 4. 10 The compound 4 was easily deprotected with 3 N HCl in EtOAc to provide product 1. The key intermediate 4 can be coupled with different substituted amine by classical EDCI/ HOBt method, and then converted into compound 6a-6m after deprotection. Using the same procedure, different moieties, such as x-amino acids, natural a-amino acids and dipeptides, were coupled with intermediate 4 to obtain AHNPA derivatives 7a-7b, 9a-9e, 12a-12b. Finally, the esters were hydrolyzed to carboxylic acid by NaOH/H 2 O in methanol, and then converted into target compounds 8a-8b, 10a-10e, and 13a-13b by deprotecting Boc group. Compounds 11a-11b containing hydroximic acid groups were obtained from 9a-9b by reacting with NH 2 OK and then cleaving Boc.

All the target compounds were tested for their inhibition against APN as listed in Table 1 . As a result, the structural addition of different alkylamine, simple benzylamine and phenethylamine can not significantly enhance the inhibitory activity compared with parent compound AHNPA (IC 50 = 140.2 lM). It seems that the substitution of phenyl ring in phenethyl group of R position can slightly contribute to the affinity. For example, para-hydroxy substitution shows up to 50 lM IC 50 value.

On the other hand, the incorporation of natural amino acids would generate compounds with similar or better inhibitory activities compared with parent compound AHNPA, while x amino acid derivative showed very poor inhibition (Table 2 ). These results suggest that the introduction of natural amino acids to AHNPA scaffold would be better than of simple nonpeptide fragment. As a zinc binding group (ZBG), hydroximate group has been used in many enzyme inhibitors especially Zn 2+ -dependent enzyme to improve affinity. 11 In our case, the AHNPA-amino acid derivatives can also enhance their activity after converting terminal carboxylate to hydroximate group. For instance, compounds 11a and 11b shows more potent inhibition than compounds 10a and 10b.

The enzyme inhibitory results unveiled that AHNPA-dipeptide derivative 13b shows the best inhibition among all target compounds. This phenomenon suggests that the dipeptide side chain would be helpful to increase the interaction with APN binding sites. Furthermore, compounds 13a and 13b were further assessed on their inhibition against HL-60 cell proliferation by using MTT method. The IC 50 values of these two compounds (13a 2.02 ± 0.13 mM and 13b 2.21 ± 0.11 mM) confirmed again that their inhibitory activities are similar with Bestatin (1.65 ± 0.09 mM) (Fig. 2) .

In order to determine the interaction between AHNPA derivatives and APN, compound 13b was docked into the active sites of APN (PDB entry: 2DQM) using SYBYL 7.0. 12 The docking results showed that the carbonyl group and amine group of compound 13b could chelate with the zinc ion in APN. The nitrophenyl group of the 13b could insert to the pocket S1 by forming hydrophobic interactions with this subsite. The phenyl ring in the terminal amino acid residue could also insert to the pocket S 0 2 , in the meantime another phenyl group closed to the AHNPA scaffold could have interaction with the pocket S 0 1 (Fig. 3 ). His 297 , Glu 298 and His 301 are the essential amino acids of the conserved sequence (HEX-XHX 18 E) in the catalytic domain of peptidase M1 family. 13 Compound 13b could form hydrogen bonds with these three residues at the distance of 2.40 Å, 3.06 Å, 2.79 Å, respectively. In addition, the carboxylate group of 13b could interact with Arg 825 and Tyr 381 residue in the S 0 2 pocket by hydrogen bond for stabilizing the reaction intermediate with the zinc ion 14 (Fig. 4 ).

In summary, we reported the synthesis and biological evaluation of a series of novel chloramphenicol amine derivatives as potent APN inhibitors. Compound 13b is the most active. Among these compounds, compound 13b not only exhibited similar enzymatic inhibition compared with natural APN inhibitor Bestatin, but also showed good cell-based inhibitory activity. Therefore, 13b could be a lead compound to search new chloramphenicol amine derivatives as APN inhibitors.

IC 50 values against APN were determined by using L-Leu-pnitroanilide as substrate and Microsomal aminopeptidase from Porcine Kidney Microsomes (Sigma) as the enzyme in 50 mM PBS, pH 7.2, at 37°C. The hydrolysis of the substrate was monitored by following the change in the absorbance measured at 405 nm with the UV-vis spectrophotometer Pharmacia LKB, Biochrom 4060. All solutions of inhibitors were prepared in the assay buffer, and pH was neutralized to 7.5 by the addition of 0.1 M HCl or 0.1 M NaOH. All inhibitors were pre-incubated with APN for 30 min at room temperature. The assay mixture, which contained the inhibitor solution (concentration dependent on the inhibitor), the enzyme solution (4 lg/mL final concentration), and the assay buffer, was adjusted to 200 lL.

HL-60 Cell was grown in RPMI1640 medium containing 10% FBS at 37°C in 5% CO 2 humidified incubator. Cell proliferation was determined by the MTT (3-[4,5-dimethyl-2-thiazolyl]-2.5-diphenyl-2H-tetrazolium bromide) assay. Briefly, cells were plated in a 96-well plate at 10,000 cells per well, cultured for 4 h in complete growth medium, then treated with 2000, 1000, 500, 250, 125 lg/ mL of compounds for 48 h. 0.5% MTT solution was added to each well. After further incubation for 4hr, formazan formed from MTT was extracted by adding DMSO and mixing for 15 min. Optical density was read with an ELISA reader at 570 nm.

The starting material 2 is a white powder (mp = 159-162°C, ½a 25 D ¼ þ28:3 (c 1, MeOH)), purchased from Wuhan Kaitong Fine Chemical Co., Ltd, China. Unless otherwise specified, other materials were purchased from commercial suppliers and used without further purification. Solvents were distilled prior to use and flash chromatography was performed using silica gel (60 Å, 200 ± 300 mesh).Melting points are uncorrected. Proton nuclear magnetic resonance ( 1 H NMR) spectra were recorded at either 300 MHz. Chemical shifts are reported in delta (d) units, parts per million (ppm) downfield from trimethylsilane. High-resolution mass spectral (HRMS) data are reported as m/e (relative intensity). Elemental analyses for compounds were performed using an elementar vario EL III CN analyzer (Germany).

To a solution of compound 2 (2.12 g, 10 mmol) in THF (10 mL) was added dropwise a solution of di-tert-butyl dicarbonate (2.93 g, 11 mmol) in THF (5 mL). After 24 h stirring at room temperature the solvent was concentrated under vacuum to leave a residue. The crude product was recrystallized with EtOAc to give white solid (2. To a solution of compound 3 (3.12 g, 10 mmol) in acetone (50 mL) containing TEMPO (0.16 g, 1 mmol) was added a 5% aqueous NaHCO 3 solution (50 ml). The mixture was cooled to 0°C and NaOCl (20.5 mL, ca. 10% w/w) was added dropwise over 15 min while following the reaction by TLC. The solution was concentrated under vacuum to remove acetone. The remaining mixture was washed with EtOAc (2 Â 10 mL), acidified to pH 1-2 by a 1 N citric acid solution, extracted with EtOAc (3 Â 20 mL), dried over Na 2 SO 4 and concentrated under reduced pressure. The crude product was purified by flash column chromatography(DCM/MeOH, 20:1 (V/ V)) to give the desired compound 4 as a white solid (0.97 g), yield: 30%, mp = 80-82°C, To a solution of compound 4 (3.26 g, 10 mmol) in dry EtOAc at 0°C was added dropwise a solution of EtOAc (10 mL) saturated with dry HCl gas. The reaction solution was stirred at 0°C for 2 h, and then the temperature is raised to room temperature and the reaction proceeds for 5 h before being concentrated in vacuo. The residue was dissolved in water (5 mL), and then washed with EtOAc (2 Â 5 mL). 1 N NaOH was added to the mixture until pH 6-7, and the solid was crystallized out. The solution was removed by filtration, and the remaining solid was sequentially washed with water and dried overnight, then recrystallized with MeOH to give a yellow crystals, yield: 74.2%, mp = 187-189°C, 

To a 150 mL solution of Compound 4 (3.26 g, 10 mmol), 1-propylamine (0.71 g, 12 mmol), and HOBt (1.62 g, 12 mmol) in dry THF, was added TEA (1.11 g, 11 mmol). The reaction mixture was gently cooled to 0°C in ice bath. To the reaction mixture was added dropwise a solution of EDCI (3.82 g, 20 mmol) in THF for 1 h. After removal of the ice bath, the reaction mixture was stirred at room temperature for 12 h and filtered to remove the precipitate. The filtrate was washed with 1 N citric acid solution, saturated NaH-CO 3 and brine, dried over Na 2 SO 4 , and evaporated in vacuo to give the crude product compound 5a (3.15 g, yield 86%). This product was used for the following reaction without further purification, yield 84%, mp = 104-106°C, To a solution of compound 5a (1.83 g, 5 mmol) in dry EtOAc at 0°C was added dropwise a solution of EtOAc (10 mL) saturated by dry HCl gas. The reaction solution was stirred at 0°C for 2 h, and then the temperature is raised to room temperature and the reaction proceeds for 5 h before being concentrated in vacuo. The residue was dissolved by saturated Na 2 CO 3 (10 mL), the aqueous solution was extracted with ethyl ether (3 Â 30 mL). The extractions were combined, washed with brine, dried over Na 2 SO 4 , and evaporated in vacuo. The residue was purified by flash column chromatography(DCM/MeOH, 6/1) to give the desired compound 6a as a white solid (1.12 g), yield 84%, mp = 118-120°C, The other compounds of 6 series were synthesized following the general procedure as described above. Compounds 8a and 8b were synthesized following the general procedure as described bellow (preparation of 12a). propanamido)-4-methylpentanoic acid (10a). To a 150 mL solution of compound 4 (3.26 g, 10 mmol), L-leucine methyl ester hydrochloride (1.81 g, 10 mmol), and HOBt (1.62 g, 12 mmol) in dry THF, was added TEA (2.22 g, 22 mmol). The reaction mixture was gently cooled to 0°C in ice bath, to the reaction mixture was added dropwise a solution of EDCI (3.82 g, 20 mmol) in THF for 1 h. After removal of the ice bath, the reaction mixture was stirred at room temperature for 12 h. and filtered to remove the precipitate. The filtrate was washed with 1 M citric acid solution, saturated NaHCO 3 and brine, dried over Na 2 SO 4 , and evaporated in vacuo. The residue was purified by flash column chromatography (EtOAc/PE, 1:4(V/V)) to give the desired compound 9a as a white solid (4.08 g), yield 88.7%, mp = 141-143°C, To a solution of compound 9a (4.53 g, 10 mmol) in MeOH at 5°C was added dropwise a solution of 1 N NaOH (12 mL). The reaction was warmed slowly to room temperature and stirred for 5 h. The solvent was concentrated under vacuum to remove the MeOH. The remaining mixture was added water (10 ml) and acidified to pH 1-2 by a 1 N citric acid solution. The precipitate was collected, washed with water (20 mL), and dried overnight. The crude product was then recrystallized with EtOAc to give the desired compound as white solid The other compounds of 10 series were synthesized following the general procedure as described above (preparation of 10a).

White solid, yield 85.9%, mp = 215-218°C, ½a 25 D ¼ þ28:4 (c 1, MeOH)

White solid, yield 85.9%, mp = 179-180°C, ½a 25 D ¼ þ21:6 (c 1, MeOH)

White solid, yield 85.9%, mp = 178-179°C, ½a 25 D ¼ þ24:8 (c 1, MeOH)

White solid, yield 85.9%, mp = 179-180°C, ½a 25 D ¼ þ26:1 (c 1, MeOH)

The reaction mixture was stirred for 1 h, and then acidified to pH 7 by acetic acid. The solvent was evaporated in vacuo to give the yellow solid. The crude product was purified by flash column chromatography

746 (m, 2H). The compound 11a was synthesized following the general procedure as described above (preparation of 1)

ESI-MS m/z: 355.6 (M+H)

(hydroxyamino)-1-oxo-3-phenylpropan-2-yl)-3-(4-nitrophenyl)propanamide (11b). The compound 11b was synthesized following the general procedure as described above

Compounds 13a, 13b were synthesized following the general procedure as described above (preparation of 10a)

3S)-2-Amino-3-hydroxy-3-(4-nitrophenyl)propanamido)-3-phenylpropanamido)-3-phenylpropanoic acid (13b). White solid, yield 85.9%, mp = 169-170°C